Boston Scientific to Introduce Two New Devices at the New Cardiovascular Horizons Conference

Boston Scientific will introduce two new devices to treat Peripheral Arterial Disease and Critical Limb Ischemia at the New Cardiovascular Horizons conference in New Orleans June 6 – 9.

The Massachusetts based company is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.

The Epic Self Expanding Stint recently received FDA approval.  The Epic Stent is designed to open blocked arteries in patients with iliac artery stenosis, a form of peripheral vascular disease associated with severe leg pain caused by insufficient blood flow.

In January, Boston Scientific announced that the ORION trial met its primary clinical endpoint.  The Epic Vascular Stent System demonstrated a low nine-month major adverse events (MAE) rate of 3.4 percent in the intent-to-treat population, which was significantly lower than the pre-specified performance goal of 17 percent (p<0.001) based on historical published outcomes for iliac stenting.

The Epic Vascular Self-Expanding Stent System received CE Mark approval and was launched in Europe and other international markets in 2009.

The other device to be unveiled in New Orleans, Truepath, allows endovascular treatment in cases that otherwise may require a patient to undergo bypass surgery or risk lower extremity amputation.

The TruePath™ CTO Device is designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature. CTOs, which represent complete artery blockages, are extremely difficult to treat with standard endovascular devices such as guidewires and other catheter-based technologies.

“The TruePath device is another example of innovation in our priority growth area targeting peripheral
vascular disease, where a significant number of patients remain undiagnosed or untreated,” said Jeff Mirviss,
President of the Boston Scientific Peripheral Interventions Division. “Addressing this
growing health problem through the use of less-invasive devices could greatly improve patient care and
ultimately save limbs.”

New Cardiovascular Horizons (NCVH) is a Peripheral Intervention Conference focusing on Peripheral Artery Disease (PAD) with a special emphasis on Critical Limb Ischemia (CLI). The goal of NCVH is to bring together key disciplines to focus on a team approach to total cardiovascular care in patients with PAD and CLI. This approach creates an environment for clinical collaboration to address the
continuum of care for the patient.

 

 

The comments are closed.